What additional information is needed to guide interventions for a patient with elevated Hemoglobin A1C (HbA1C) of 9.2%, polydipsia, and polyuria?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 26, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Assessing medication adherence would be the most helpful information in deciding the next interventions for EC. When a patient with diabetes returns with an elevated A1C of 9.2% and symptoms of polyuria and polydipsia (increased urination and thirst), understanding whether they are taking their prescribed medications as directed is crucial 1. Poor medication adherence is a common cause of uncontrolled diabetes, and identifying this issue would allow for targeted interventions such as simplifying the medication regimen, addressing barriers to adherence, or providing education about the importance of consistent medication use. While assessing physical activity, food intake, and screening for depression are all important components of diabetes management, medication adherence directly impacts glycemic control and should be addressed first when symptoms of hyperglycemia are present. Understanding EC's medication-taking behavior provides the foundation for any additional interventions that may be needed to improve their diabetes control and prevent complications. Some key considerations for EC's treatment plan, as outlined in the standards of care in diabetes-2024, include the use of combination therapy or more potent glucose-lowering agents when A1C is ≥1.5% above the individualized glycemic goal, and the potential benefits of GLP-1 RAs and tirzepatide in improving glycemic control and reducing cardiovascular risk 1. However, assessing medication adherence is the first step in determining the best course of action for EC, as it will inform whether adjustments to the medication regimen or other interventions are needed to achieve optimal glycemic control.

From the FDA Drug Label

The FDA drug label does not answer the question.

From the Research

Assessing Additional Information for EC's Interventions

To decide on the next interventions for EC, it is crucial to gather more information about her current situation. The following points highlight the most helpful additional information:

  • Assessing medication adherence: This is a critical aspect, as studies have shown that non-adherence to medication is a significant issue in patients with chronic illnesses, including diabetes 2, 3, 4, 5. Assessing EC's medication adherence can help identify any potential issues with her current treatment plan.
  • Factors affecting adherence: Research has identified various factors that can affect adherence, including patient-perceived barriers, type of delivery device, and cost of medication 6. Understanding these factors can help healthcare providers develop targeted interventions to improve EC's adherence.
  • Patient education and support: Studies have emphasized the importance of patient education and support in improving medication adherence 2, 5. Assessing EC's understanding of her medication regimen and providing additional education and support can help improve her adherence.
  • Monitoring and follow-up: Regular monitoring and follow-up can help identify any issues with EC's medication adherence and allow for timely interventions 2, 4. This can include regular check-ins with healthcare providers, monitoring of blood glucose levels, and adjustments to her medication regimen as needed.

Comparison of Options

The options for assessing additional information for EC's interventions are:

  • Assessing medication adherence: This is a crucial aspect of EC's care, as non-adherence can have significant consequences for her health 2, 3.
  • Assessing daily physical activity: While physical activity is an important aspect of diabetes management, it may not be directly related to EC's current issue with medication adherence.
  • Assessing 24-hour food intake: Similar to physical activity, food intake is important for diabetes management, but it may not be directly related to EC's medication adherence.
  • Assessing patient for depression: Depression can be a comorbidity with diabetes, but it may not be directly related to EC's current issue with medication adherence.

Based on the available evidence, assessing medication adherence is the most critical aspect of EC's care at this time 2, 3, 4, 5, 6.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Assessing medication adherence: options to consider.

International journal of clinical pharmacy, 2014

Research

Medication adherence: understanding the issues and finding solutions.

British journal of community nursing, 2020

Related Questions

What is the recommendation for evaluation and treatment to improve long-term adherence, considering a social work or psychology (psych) consultation?
What is an enhanced medication adherence plan for fluoxetine (selective serotonin reuptake inhibitor)?
What is the best course of action for a 56-year-old female with a history of anxiety, gout, and depression, currently taking Duloxetine, Bupropion, Gabapentin, Cymbalta (Duloxetine), and Buspar (Buspirone), who reports a slight increase in anxiety due to life situations and requests a dose increase of Buspar?
What should be done if a patient with atrial fibrillation is not taking their prescribed medications, including Flecainide (flecainide), Metoprolol (metoprolol), and Eliquis (apixaban)?
What is the workup for a 54-year-old male experiencing recurrent headaches (HAs), dry cough, and severe neck and rear headaches during climax, with a history of hypertension (HTN) and tinnitus, currently taking lisinopril (Lisinopril)-hydrochlorothiazide (HCTZ), and previously taking amlodipine (Amlodipine) and losartan (Losartan)-amlodipine, with an upcoming magnetic resonance imaging (MRI) of the brain?
What is the next pharmacologic intervention for a patient with a stable Hemoglobin A1C (HbA1C) level of 7.2% and no adverse effects from metformin (Metformin) 500 milligrams twice daily?
What is the recommended target Hemoglobin A1C (HbA1C) level for EC to prevent microvascular and macrovascular complications?
What are the clinical features of hyperactive delirium?
What other aspect of diabetes management is crucial for a patient initiating basal insulin and metformin therapy?
At what age should an 8-year-old child with a Body Mass Index (BMI) at the 50th percentile be screened for diabetes mellitus?
What is the next step for a 21-year-old pregnant woman with a glucose level of 154 mg/dL after a non-fasting 50-gram glucose screening test (Glucose Challenge Test, GCT)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.